Aerosolized antimicrobial therapy in acutely ill patients.
Recent data are sparking renewed interest in therapy with aerosolized antimicrobials in critically ill patients as well as other populations such as those with neutropenia, human immunodeficiency virus infection, and cystic fibrosis. Pneumonia is a common complication in these patients and is associated with substantial morbidity and increased mortality. Clinical trials evaluated aerosolized antimicrobials for the prevention and treatment of pneumonia in hospitalized patients. In addition, factors that affect the pulmonary deposition of aerosolized drugs in mechanically ventilated patients were identified.
Wood
G C
GC
Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis 38163, USA.
Boucher
B A
BA
D000208:Acute Disease; D000280:Administration, Inhalation; D000336:Aerosols; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000336:Aerosols; D000890:Anti-Infective Agents